赛托生物董秘李璐荣获“金牛董秘奖”

Core Viewpoint - The 2025 High-Quality Development Forum for Listed Companies and the 27th Golden Bull Award Ceremony took place in Nantong, Jiangsu, highlighting the importance of transparency and investor relations in the capital market [1][4]. Group 1: Company Overview - Saito Bio focuses on the research and production of steroid drug intermediates, leveraging gene engineering and microbial transformation technologies [4]. - The company has achieved large-scale application of biopharmaceutical technology in the steroid drug sector through years of independent research and technology introduction [4]. Group 2: Awards and Recognition - The Golden Bull Award is a prestigious evaluation event organized by China Securities Journal, emphasizing transparency and professionalism in the capital market [4][5]. - The awards include categories such as "Most Investment Value Award," "Golden Bull Outstanding Entrepreneur Award," and "Golden Bull Secretary Award," with the latter recognizing outstanding performance in corporate governance and investor relations [5]. Group 3: Investor Relations - Saito Bio has prioritized information disclosure and investor relations management since its listing, actively engaging with investors through various channels and timely responses [4]. - The company has received positive feedback from investors for its commitment to transparency and effective communication [4].